Logo image of PGEN

PRECIGEN INC (PGEN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PGEN - US74017N1054 - Common Stock

3.675 USD
+0.07 (+2.08%)
Last: 12/8/2025, 11:42:59 AM
Fundamental Rating

3

PGEN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While PGEN seems to be doing ok healthwise, there are quite some concerns on its profitability. PGEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PGEN has reported negative net income.
In the past year PGEN has reported a negative cash flow from operations.
In the past 5 years PGEN reported 4 times negative net income.
In the past 5 years PGEN always reported negative operating cash flow.
PGEN Yearly Net Income VS EBIT VS OCF VS FCFPGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

With a Return On Assets value of -248.66%, PGEN is not doing good in the industry: 92.28% of the companies in the same industry are doing better.
With a Return On Equity value of -1017.16%, PGEN is not doing good in the industry: 81.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -248.66%
ROE -1017.16%
ROIC N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
PGEN Yearly ROA, ROE, ROICPGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

PGEN's Gross Margin of 30.32% is fine compared to the rest of the industry. PGEN outperforms 72.88% of its industry peers.
PGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PGEN Yearly Profit, Operating, Gross MarginsPGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

PGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
PGEN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PGEN has been reduced compared to 5 years ago.
PGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PGEN Yearly Shares OutstandingPGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
PGEN Yearly Total Debt VS Total AssetsPGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

PGEN has an Altman-Z score of -14.40. This is a bad value and indicates that PGEN is not financially healthy and even has some risk of bankruptcy.
PGEN has a worse Altman-Z score (-14.40) than 79.85% of its industry peers.
A Debt/Equity ratio of 2.22 is on the high side and indicates that PGEN has dependencies on debt financing.
With a Debt to Equity ratio value of 2.22, PGEN is not doing good in the industry: 80.79% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.22
Debt/FCF N/A
Altman-Z -14.4
ROIC/WACCN/A
WACC8.78%
PGEN Yearly LT Debt VS Equity VS FCFPGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

PGEN has a Current Ratio of 4.04. This indicates that PGEN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.04, PGEN perfoms like the industry average, outperforming 47.83% of the companies in the same industry.
A Quick Ratio of 3.95 indicates that PGEN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.95, PGEN is in line with its industry, outperforming 48.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 3.95
PGEN Yearly Current Assets VS Current LiabilitesPGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

PGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -204.76%.
PGEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.20%.
PGEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -46.64% yearly.
EPS 1Y (TTM)-204.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1077.78%
Revenue 1Y (TTM)59.2%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%206.61%

3.2 Future

Based on estimates for the next years, PGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 33.15% on average per year.
The Revenue is expected to grow by 155.65% on average over the next years. This is a very strong growth
EPS Next Y-155.49%
EPS Next 2Y21.87%
EPS Next 3Y30.42%
EPS Next 5Y33.15%
Revenue Next Year312.21%
Revenue Next 2Y388.31%
Revenue Next 3Y267.77%
Revenue Next 5Y155.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PGEN Yearly Revenue VS EstimatesPGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
PGEN Yearly EPS VS EstimatesPGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PGEN Price Earnings VS Forward Price EarningsPGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PGEN Per share dataPGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as PGEN's earnings are expected to grow with 30.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.87%
EPS Next 3Y30.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECIGEN INC

NASDAQ:PGEN (12/8/2025, 11:42:59 AM)

3.675

+0.07 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-17 2026-03-17/amc
Inst Owners66.79%
Inst Owner Change34.86%
Ins Owners2.73%
Ins Owner Change-0.01%
Market Cap1.30B
Revenue(TTM)6.31M
Net Income(TTM)-425.87M
Analysts80
Price Target8.67 (135.92%)
Short Float %9.46%
Short Ratio5.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-500.32%
Min EPS beat(2)-993.91%
Max EPS beat(2)-6.73%
EPS beat(4)1
Avg EPS beat(4)-247.59%
Min EPS beat(4)-993.91%
Max EPS beat(4)14.22%
EPS beat(8)1
Avg EPS beat(8)-134.84%
EPS beat(12)2
Avg EPS beat(12)-89.42%
EPS beat(16)5
Avg EPS beat(16)-84.11%
Revenue beat(2)2
Avg Revenue beat(2)249.41%
Min Revenue beat(2)25.88%
Max Revenue beat(2)472.94%
Revenue beat(4)3
Avg Revenue beat(4)162.05%
Min Revenue beat(4)-13.58%
Max Revenue beat(4)472.94%
Revenue beat(8)3
Avg Revenue beat(8)64.9%
Revenue beat(12)3
Avg Revenue beat(12)31.35%
Revenue beat(16)3
Avg Revenue beat(16)4.6%
PT rev (1m)3.03%
PT rev (3m)3.03%
EPS NQ rev (1m)-56.25%
EPS NQ rev (3m)-47.04%
EPS NY rev (1m)-120.55%
EPS NY rev (3m)-119.17%
Revenue NQ rev (1m)-42.33%
Revenue NQ rev (3m)-42.33%
Revenue NY rev (1m)26.84%
Revenue NY rev (3m)25.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 206.1
P/FCF N/A
P/OCF N/A
P/B 31.06
P/tB 56.2
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.02
BVpS0.12
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -248.66%
ROE -1017.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.32%
FCFM N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 2.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110.36%
Cap/Sales 47.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 3.95
Altman-Z -14.4
F-Score3
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)86.13%
Cap/Depr(5y)70.81%
Cap/Sales(3y)87.22%
Cap/Sales(5y)63.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-204.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1077.78%
EPS Next Y-155.49%
EPS Next 2Y21.87%
EPS Next 3Y30.42%
EPS Next 5Y33.15%
Revenue 1Y (TTM)59.2%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%206.61%
Revenue Next Year312.21%
Revenue Next 2Y388.31%
Revenue Next 3Y267.77%
Revenue Next 5Y155.65%
EBIT growth 1Y-12.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.14%
EBIT Next 3Y25.15%
EBIT Next 5YN/A
FCF growth 1Y-12.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.1%
OCF growth 3YN/A
OCF growth 5YN/A

PRECIGEN INC / PGEN FAQ

What is the fundamental rating for PGEN stock?

ChartMill assigns a fundamental rating of 3 / 10 to PGEN.


What is the valuation status for PGEN stock?

ChartMill assigns a valuation rating of 1 / 10 to PRECIGEN INC (PGEN). This can be considered as Overvalued.


What is the profitability of PGEN stock?

PRECIGEN INC (PGEN) has a profitability rating of 1 / 10.


How financially healthy is PRECIGEN INC?

The financial health rating of PRECIGEN INC (PGEN) is 4 / 10.